IP Library Granted Patent US 10,695,443
Granted Patent B2
US 10,695,443 · App. 16/201,937 · Granted Jun 30, 2020

Exosome transfer of nucleic acids to cells

Inventors: Jan Lötvall (Boston, MA); Hadi Valadi (Göteborg, SE)
Assignee: Codiak BioSciences, Inc.
A61K48/0033C12N15/113C12N15/87A61K48/00C12N2310/14C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,443
App. No.
16/201,937
Granted
Jun 30, 2020
Kind
B2
Abstract

Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.

Claims (16)

1. A composition comprising exosomes, wherein the exosomes comprise one or more non-autologous nucleic acid constructs selected from mRNA, tRNA, rRNA, siRNA, microRNA, regulating RNA, non-coding and coding RNA, DNA fragments, or DNA plasmids, and wherein the exosomes are produced from a donor cell that has been genetically modified, such that one or more genes that are naturally expressed in the donor cell has been disrupted or mutated.

2. The composition of claim 1 , wherein the donor cell expresses the one or more non-autologous nucleic acid constructs or has been transfected with the one or more non-autologous nucleic acid constructs.

3. The composition of claim 1 , wherein the donor cell is from a person with a particular disease or condition.

4. The composition of claim 1 , wherein the one or more non-autologous nucleic acid constructs are introduced directly into the exosomes.

5. The composition of claim 1 , wherein the exosomes are produced from in vitro growing cells.

6. The composition of claim 5 , wherein the exosomes are isolated from cell culture supernatant.

7. The composition of claim 1 , wherein the exosomes isolated from the genetically modified donor cell do not comprise the one or more genes that have been disrupted or mutated.

8. The composition of claim 2 , wherein the donor cell has been further genetically modified, such that the expression of the non-autologous nucleic acid constructs is upregulated in the donor cell.

9. The composition of claim 8 , wherein the exosomes isolated from the further genetically modified donor cell comprise greater amount of the non-autologous nucleic acid construct, compared to exosomes isolated from a donor cell that has not been further genetically modified.

10. The composition of claim 4 , wherein the one or more non-autologous nucleic acid constructs are introduced into the exosomes by transformation or transfection.

11. The composition of claim 4 , wherein the one or more non-autologous nucleic acid constructs are introduced into the exosomes by microinjection.

12. The composition of claim 4 , wherein the one or more non-autologous nucleic acid constructs are introduced into the exosomes by electroporation.

13. The composition of claim 1 , wherein the exosomes further comprise a membrane bound protein.

14. The composition of claim 13 , wherein the membrane bound protein comprises CD63, CD54, CD43, and/or WIC class I.

15. The composition of claim 1 , wherein the non-autologous nucleic acid constructs are sense or antisense nucleotides.

16. The composition of claim 15 , wherein the non-autologous nucleic acid constructs are introduced directly into the exosomes by electroporation.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2023
From: CODIAK BIOSCIENCES, INC.
To: LONZA SALES AG
Reel/Frame 065183/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: VL27, INC.
To: CODIAK BIOSCIENCES, INC.
Reel/Frame 048299/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2018
From: EXOSOME VENTURE AB
To: VL27, INC.
Reel/Frame 047800/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2018
From: LÖTVALL, JAN; VALADI, HADI; NILSSON, JONAS
To: EXOSOME VENTURE AB
Reel/Frame 047629/0211 →
Continuity (6)
Continuation 15857539 · Dec 28, 2017
Continuation 15476844 · Mar 31, 2017
Continuation In Part 14750457 · Jun 25, 2015
Continuation 11799148 · Apr 30, 2007
Provisional Application 60797149 · May 3, 2006
Related Publication 20190111155A1 · Apr 18, 2019
Cited By (9)
US 12,384,828 US 12,433,910 US 12,441,996 US 12,458,606 US 12,521,449 US 12,522,826 US 12,644,134 US 12,697,307 US 12,709,747